S'abonner

Neutrophils drive type I interferon production and autoantibodies in patients with Wiskott-Aldrich syndrome - 06/11/18

Doi : 10.1016/j.jaci.2017.11.063 
Karla E. Cervantes-Luevano, PhD a, Nicoletta Caronni, PhD a, Maria C. Castiello, PhD b, Elena Fontana, PhD c, d, Giulia M. Piperno a, Asma Naseem, PhD a, Paolo Uva, PhD e, Marita Bosticardo, PhD b, f, Genni E. Marcovecchio, PhD b, Luigi D. Notarangelo, MD f, Maria P. Cicalese, MD, PhD b, g, Alessandro Aiuti, MD b, g, Anna Villa, MD b, d, Federica Benvenuti, PhD a,
a International Centre for Genetic Engineering and Biotechnology, Trieste, Italy 
b San Raffaele Telethon Institute for Gene Therapy (TIGET), Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy 
c Humanitas Clinical and Research Center, Rozzano, Milan, Italy 
d Milan Unit, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy 
e CRS4, Science and Technology Park Polaris, Pula, Italy 
f Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md 
g San Raffaele Telethon Institute for Gene Therapy and the Pediatric Immunohematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy 

Corresponding author: Federica Benvenuti, PhD, Cellular Immunology, Area di Ricerca, Padriciano 99, 34149 Trieste, Italy.Cellular Immunology, Area di RicercaPadriciano 99Trieste34149Italy

Abstract

Background

Wiskott-Aldrich syndrome (WAS) is a rare primary immunodeficiency caused by mutations in Wiskott-Aldrich syndrome protein (WASp), a key regulator of cytoskeletal dynamics in hematopoietic cells. A high proportion of patients experience autoimmunity caused by a breakdown in T- and B-cell tolerance. Moreover, excessive production of type I interferon (IFN-I) by plasmacytoid dendritic cells (pDCs) contributes to autoimmune signs; however, the factors that trigger excessive innate activation have not been defined.

Objective

Neutrophil extracellular traps (NETs) emerged as major initiating factors in patients with diseases such as systemic lupus erythematosus and rheumatoid arthritis. In this study we explored the possible involvement of aberrant neutrophil functions in patients with WAS.

Methods

We evaluated the expression of a set of granulocyte genes associated with NETs in a cohort of patients with WAS and the presence of NET inducers in sera. Using a mouse model of WAS, we analyzed NET release by WASp-null neutrophils and evaluated the composition and homeostasis of neutrophils in vivo. By using depletion experiments, we assessed the effect of neutrophils in promoting inflammation and reactivity against autoantigens.

Results

Transcripts of genes encoding neutrophil enzymes and antimicrobial peptides were increased in granulocytes of patients with WAS, and serum-soluble factors triggered NET release. WASp-null neutrophils showed increased spontaneous NETosis, induced IFN-I production by pDCs, and activated B cells through B-cell activating factor. Consistently, their depletion abolished constitutive pDC activation, normalized circulating IFN-I levels, and, importantly, abolished production of autoantibodies directed against double-stranded DNA, nucleosomes, and myeloperoxidase.

Conclusions

These findings reveal that neutrophils are involved in the pathogenic loop that causes excessive activation of innate cells and autoreactive B cells, thus identifying novel mechanisms that contribute to the autoimmunity of WAS.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Neutrophil extracellular traps, Wiskott-Aldrich syndrome, type I interferon, autoimmunity

Abbreviations used : APC, BAFF, BM, CFSE, CRAMP, DEFA1/3, dsDNA, ELANE, GAPDH, G-CSF, HD, IFN-I, MPO, NE, NET, pDC, PDCA-1, PE, PFA, PMA, RA, SLE, TLR, WAS, WASp, WT


Plan


 Supported by Italian Telethon grant GGP14281 to F.B. and the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (to L.D.N.). K.E.C.-L. is supported by an ICGEB postdoctoral fellowship and CONACyT postdoctoral fellowship. N.C. is supported by an AIRC fellowship. The autoantibody arrays (UT Southwestern Medical Center and Microarray Core Facility) were performed in collaboration with Q.-Z. Li (Center for Immunology, University of Texas Southwestern Medical Center at Dallas, Dallas, Tex).
 Disclosure of potential conflict of interest: A. Aiuti has received a grant from GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.


© 2018  American Academy of Allergy, Asthma & Immunology. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 142 - N° 5

P. 1605 - novembre 2018 Retour au numéro
Article précédent Article précédent
  • Mutations affecting the actin regulator WD repeat–containing protein 1 lead to aberrant lymphoid immunity
  • Laurène Pfajfer, Nina K. Mair, Raúl Jiménez-Heredia, Ferah Genel, Nesrin Gulez, Ömür Ardeniz, Birgit Hoeger, Sevgi Köstel Bal, Christoph Madritsch, Artem Kalinichenko, Rico Chandra Ardy, Bengü Gerçeker, Javier Rey-Barroso, Hanna Ijspeert, Stuart G. Tangye, Ingrid Simonitsch-Klupp, Johannes B. Huppa, Mirjam van der Burg, Loïc Dupré, Kaan Boztug
| Article suivant Article suivant
  • Thirdhand smoke component can exacerbate a mouse asthma model through mast cells
  • Mang Yu, Kaori Mukai, Mindy Tsai, Stephen J. Galli

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.